Infographic: we need minimum reporting standards for biologies

摘要

Biologic therapies, including platelet rich plasma (PRP) and mesenchymal stem cells, are now widely used to treat a spectrum of sports injuries without robust clinical evidence of efficacy. Physicians have a duty to use biologic therapies responsibly, using the best available research evidence to guide treatment decisions for patients. A large number of variables, including processing details, laboratory conditions and formulation composition, influence the effect of biologic therapies. Insufficient reporting of these critical variables is widespread, with only 11.5% of clinical studies investigating the use of PRP to manage musculoskeletal conditions, describing the methodology adequately.